Monash IVF Group Limited
Level 1, 510 Church St
Cremorne VIC 3121 Australia
+61 3 9420 8235
groupenquiries@monashivf.com
monashivfgroup.com.au
ABN 90 169 302 309

ASX Announcement

Monash IVF Group Limited (ASX:MVF)

26 November 2026

Monash IVF Group 2026 Annual General Meeting Presentation

The Manager
ASX Market Announcements Office
Australian Securities Exchange

Dear Manager

Monash IVF Group Limited – Annual General Meeting Presentation

In accordance with the ASX Listing Rules, attached is the 2026 Annual General Meeting (AGM) Presentation to be delivered at Monash IVF Group Limited's 2026 AGM to be held today, Thursday 26 November 2026 at 2.00pm (AEDT).

Yours faithfully

Rebecca Dean
General Counsel & Company Secretary

Authorised by the Board of Directors.

For further information please contact:

Rebecca Dean
General Counsel & Company Secretary
Monash IVF Group
T: +61 3 9420 8235



2026 Annual General Meeting

26 November 2026

Disclaimer

The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ("MVF") (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF's activities as at the date of this presentation. The information does not purport to be complete, is given in summary and may change without notice.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. The presentation does not constitute or form part of an offer to buy or sell MVF securities.

This presentation contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors are not all within the control of MVF and cannot be predicted by MVF and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which MVF operate. They also include general economic conditions, exchange rates, interest rates, the regulatory environment, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised.

None of MVF (and their respective officers, employees or agents) (the Relevant Persons) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward-looking statement or any outcomes expressed or implied in any forward-looking statements. The forward-looking statements in this presentation reflect views held only at the date of this presentation. Except as required by applicable law or the ASX Listing Rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any forward-looking statements, whether as a result of new information or future events. Statements about past performance are not necessarily indicative of future performance.


Certain jurisdictions may restrict the release, publication or distribution of this presentation. Persons in such jurisdictions should observe such restrictions. To the extent permitted by law the Relevant Persons do not accept liability for any use of this presentation, its contents or anything arising in connection thereto including any liability arising from the fault or negligence none of the Relevant Persons.

This presentation includes a number of non-IFRS measures which includes EBITDA, Underlying EBITDA, Underlying EBIT and Underlying NPAT. These non-IFRS measures are used by management to measure the performance of the business. These measures have not been subject to audit review.

Acknowledgement of Country

In the spirit of reconciliation, Monash IVF acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community.

We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples present here today.



Agenda

- Chair's Address
- Chief Executive Officer Address
- Voting Instructions
- How to Ask a Question
- Business of the AGM
- Questions
- Meeting close

Monash IVF Group

Chair's Address

Ms Catherine West





FY26 performance and FY27 priorities

Nurture 2030 provides the framework for restoring sustainable growth, with a clear focus on disciplined execution, productivity and long-term shareholder value.

FY26 in numbers

$269.5m
Group revenue

$53.4m
Underlying EBITDA

$16.1m
Underlying NPAT

2.5cps
Total FY26 dividends



Payout ratio, in line with our Dividend Policy

1.3cps
Final dividend, fully franked

Board priorities

Patient safety, quality and trust
Central to Board oversight as the sector moves to nationally consistent standards

Nurture 2030
Vision 2026 complete; focus on sustainable long-term shareholder value

FY27 outlook

- Q1 FY27 earnings challenged
- Productivity program commenced
- Oct–Nov earnings improved on Q1
- Trading update at FY27 half year

Board focus: disciplined execution, productivity and sustainable returns.

Chair's Address

Thank you.



Monash IVF Group

Managing Director and CEO's Report

Dr Victoria Atkinson



FY26 Overview

FY26 Revenue	FY26 Underlying EBITDA[2]	FY26 Underlying EBITDA[2] Margin %	1H26 Domestic Stimulated Cycle Market Share[3]	2H26 Domestic Stimulated Cycle Market Share[3]
$269.5m Down 0.9% vs FY25	$53.4m Down 19.5% vs FY25	19.8% Down 460 bps vs FY25	19%	20.2% up 120bps vs 1H26

FY26 Underlying NPAT[2]	FY26 Fully Franked Dividend	FY26 Stimulated cycles[1]	1H26 Domestic Stimulated Cycles	2H26 Domestic Stimulated Cycles
$16.1m Down 41.2% vs FY25	2.5 cps 60% payout ratio as per policy	11,423 Down 2.9% vs FY25	-11.7% vs pcp	-1.6% vs pcp

1. Egg collections in Australia and International
2. Non-IFRS measures
3. MBS items 13200/1

FY26 Operational Overview

Domestic business units and International performance

Domestic: business units

Ultrasound scans
82,905
Down 0.94% vs FY25

- WA acquisition ramping in line
- In-house sonographer training pipeline

Embryos screened
21,079
Consistent with FY25

- PGT-A, PGT-M, PGT-SR all up >20%
- Faster turnaround times

Day surgery cases
7,980
Up 1% vs FY25

- Clayton volumes moved to Cremorne
- Brisbane DSU opened July 26

International: record performance across Asia

Stimulated cycles
1,366
Up 8.3% vs FY25

Patient treatments
2,554
Up 7.1% vs FY25

Revenue
$21.2m
Up 15% vs FY25

EBITDA
$4.2m
Up 9.6% vs FY25

EBITDA margin
19.8%
Down 457 bps vs FY25

- **Kuala Lumpur:** revenue +12%, EBITDA +7%
- **Singapore:** revenue +9%, EBITDA +82%
- **Johor Bahru:** revenue +73%, EBITDA +245%; Singapore–Johor rail link opens Jan 2027
- **Bali:** stronger profitability; platform for growth

FY26 Year in Review

11,423 Stimulated cycles

19.5% Australian market Share

72.7 Group NPS

42.1% Clinical pregnancy rate - women under 43

#2 in Market Share Across Australian stimulated cycle market in FY26

13 new fertility specialists

3 new trainees

Patients & Clinical Outcomes

Supporting more patient episodes, every month.

3,000+

1,700	660	6,900
IVF Patients	Day surgery patients	Scans

11,423 stimulated cycles
▼ 2.9% vs FY25

20.2% 2H26 domestic stimulated cycle market share
▲ 1.2% vs 1H26

42.1% Women under 43

44% Women under 40

FY26 Clinical Pregnancy Rates both above ANZARD benchmark

"Patient outcomes, experience and trust are the lead indicators of sustainable financial performance."

Dr Victoria Atkinson
Managing Director & CEO

CEO Priorities

12 months in: significant progress on the three priorities set in February, with the benefits now showing in how the business operates and performs

Restoring Sustainable Growth

- Operational excellence program under way – data-led, with tighter workforce, procurement, asset and cost discipline
- Capex tracking at less than half of FY26 levels
- Brisbane clinic and day surgery commissioned in Q1; Clayton on track and on budget for December
- Cremorne theatre utilisation more than doubled in Q1

Strategic Direction


- Nurture 2030 launched, setting clear FY27 priorities for our clinics and teams
- Victorian strategy under way: market share stabilising, modest volume growth, IVF NPS up 7.7 points in Q1
- Asia fully unified: Bali now under the Kuala Lumpur hub, with a clearer regional strategy

Building Leadership Capability

- Peter Orlowski started as CIO and is already shaping strategy
- Matt Harrington appointed CFO from 4 January 2027 (ex-AustralianSuper, Australian Unity), completing the refreshed ELT
- Stronger SLT, with national leadership in genetics, donor services and diagnostics
- Medical leadership elevated and consolidated

Q1 performance


- Domestic stimulated cycles softer, FETS stable pcp
- Stimulated cycles increased on Q4
- International continued growth
- Pricing increases nationally
- Structural productivity program underway
- Capital expenditure tracking <50% FY26
- 2 specialists added with positive Q2 doctor pipeline
- Q2 performance increased in all states



Market share

A flat, volatile market: group share is steady at 19.4%, with mixed movement by state

Australian market: monthly change, % (Jul–Sep)



-0.5%	Stimulated cycles, Q1 FY27
-2.2%	FET, 3-month rolling, Q1 FY27

19.4%
Group share, 12-month rolling

19.5%
FY26 group share

Share movement by state, Q1

↑ Victoria	+190bps Q4 to Q1, in a market down 2.7%
→ NSW	Stabilised in a declining market
↑ Queensland	Significant share growth
↑ WA	Strong growth; more than a third of market
↓ Repromed	Challenged by competition; recovery Oct–Nov

Research that moves from discovery to care

BREAKTHROUGH RESEARCH AND CLINICAL TRIAL

mitoHOPE

- $15m MRFF collaboration with Monash University advancing mitochondrial donation, helping people with mitochondrial disease achieve a family
- Pre-clinical research and training under way; clinical training and trial phases in preparation
- Building the evidence, capability and approvals for clinical translation

$15m
MRFF PROGRAM


RESEARCH TO CLINICAL PRACTICE

Felix™ sperm separation

- 10-year research and innovation partnership with Memphasys
- Multi-centre sibling split study completed, demonstrating improved embryo utilisation
- Faster, more gentle processing with fewer handling steps, reducing risk
- Full Monash IVF Group rollout of the technology during Q2 and Q3

6 min
SPERM SEPARATION

RESEARCH › **EVIDENCE** › **GOVERNED IMPLEMENTATION** › **PATIENT CARE**



Innovation with a clear pathway to patient impact

FY27 Priorities & Outlook

Deliver key strategic initiatives under Nurture 2030

PRIORITY 1

Elevated Patient Experience

Continue to evolve differentiated patient experience driving commercial outcomes:

- Patient attraction
- Conversion
- Retention
- Referral

Innovative model to partner with consumers

PRIORITY 2

Volume and Market Share Growth

- Harness current business and strategic initiatives to grow the market share
- Optimise current specialist capacity and convert the positive doctor pipeline
- New partnership models in a changing industry
- Drive data-based marketing strategy

PRIORITY 3

Deliver operational excellence

- Iterative cost base management delivering $8-11 million annualised
- Continued Capital expenditure discipline
- Further service line review and data-led identification of operational efficiency gains

PRIORITY 4

Be accreditation ready

- Prepare for National Standards from 2027–2028, administered by the Australian Commission on Safety and Quality in Health Care
- Position Monash IVF for industry reshaping over the next 12–18 months
- Unwavering focus on clinical outcomes, safety and governance

Purpose

Nurturing possibility for every reproductive health journey

Strategic Pillars

- Connected Patient Ecosystem
- Clinical Excellence and Safety
- Industry-Leading Talent
- Science, Research and Technology
- Sustainable Growth and Performance

Enablement Layer

- Data, Digital and AI
- Progressive Leadership

Service Domains

- Fertility Care
- Diagnostics
- Reproductive Health

Managing Director & CEO's Address

Thank you.




Monash IVF Group

Voting instructions

Voting Instructions


1. Click the Get a Voting Card box on your screen
2. Enter your Shareholder or Proxy Details and click Submit Details and Vote
3. When the Voting Card pops up, select either Full Vote or Partial Vote
4. Select your voting preference and then click Submit Vote or Submit Partial Vote
5. If you require Assistance, please call Link Market Services on 1800 990 363
6. Voting cards are available for Holders attending the meeting in person



How to Ask a Question

1. In person at the meeting
2. Virtually
   - Click the Ask a Question box on your screen
   - Select the Item of Business your question relates to
   - Type your question in the space provided*
   - Click Submit Question

   *Please note, the space provided has a limit of 512 characters
3. Verbally via the teleconference facility
   - Shareholders must use their unique PIN provided to them by Link Market Services.
   - If you require Assistance, please call Link Market Services on 1800 990 363





Monash IVF Group

Business of the AGM

Resolution 1

Financial Report

To receive and consider the Financial Report, the Directors' Report and the Auditor's Report for the year ended 30 June 2026.



Resolution 2

Adoption of the Remuneration Report

To adopt the Remuneration Report, which forms part of the Directors' Report for the year ended 30 June 2026.

Non-binding advisory vote under section 250R of the Corporations Act 2001 (Cth). A voting exclusion statement applies.

Proxy Position: Resolution 2

Adoption of the Remuneration Report

Proxy position	In favour	Open (undirected proxies)	Against	Total valid votes	Abstain
Votes	146,461,372	731,382	2,601,020	149,793,774	341,434
Holders	84	38	71	–	11
Percentage	97.78%	0.49%	1.74%	–	–

Resolution 3a

Re-election Ms Catherine West as a Director

Ms Catherine West

"That Ms Catherine West, an Independent Non-Executive Director of the Company, and being eligible, be re-elected as a Director of the Company."



Proxy Position: Resolution 3a

Re-election of Ms Catherine West as Director

Proxy position	In favour	Open (undirected proxies)	Against	Total valid votes	Abstain
Votes	147,737,209	739,994	1,627,637	150,104,840	371,104
Holders	120	40	38	–	10
Percentage	98.42%	0.49%	1.08%	–	–

Resolution 3b

Election of Dr Dwayne Crombie as a Director

Dr Dwayne Crombie

"That Dr Dwayne Crombie, an Independent Non-Executive Director of the Company, and being eligible, be elected as a Director of the Company."



Proxy Position: Resolution 3b

Election of Dr Dwayne Crombie as Director

Proxy position	In favour	Open (undirected proxies)	Against	Total valid votes	Abstain
Votes	148,499,853	740,502	1,183,929	150,424,284	51,660
Holders	128	41	33	–	6
Percentage	98.72%	0.49%	0.79%	–	–

Resolution 4a

Approval of grant of performance rights to the Chief Executive Officer (CEO) and Managing Director under the Long-Term Incentive Plan.

To consider and, if thought fit, to pass the following resolution of the company:

*"That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 279,383 performance rights to Dr Victoria Atkinson, Chief Executive Officer and Managing Director, as her Long-Term Incentive grant for **FY2026** on the terms described in the Explanatory Notes accompanying this Notice of Meeting."*

Proxy Position: Resolution 4a

Grant of performance rights to the CEO and Managing Director (FY2026 LTI)

Proxy position	In favour	Open (undirected proxies)	Against	Total valid votes	Abstain
Votes	146,230,088	733,932	3,112,705	150,076,725	399,219
Holders	67	40	92	–	10
Percentage	97.44%	0.49%	2.07%	–	–

Resolution 4b

Approval of grant of performance rights to the Chief Executive Officer (CEO) and Managing Director under the Long-Term Incentive Plan.

To consider and, if thought fit, to pass the following resolution of the company:


*"That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of 504,070 performance rights to Dr Victoria Atkinson, Chief Executive Officer and Managing Director, as her Long-Term Incentive grant for **FY2027** on the terms described in the Explanatory Notes accompanying this Notice of Meeting."*

Proxy Position: Resolution 4b

Grant of performance rights to the CEO and Managing Director (FY2027 LTI)

Proxy position	In favour	Open (undirected proxies)	Against	Total valid votes	Abstain
Votes	146,421,936	733,932	3,110,857	150,266,725	209,219
Holders	69	40	91	–	9
Percentage	97.44%	0.49%	2.07%	–	–





Questions

Monash IVF Group



Meeting close

Thank you for attending the 2026 Monash IVF Group AGM